Repare Therapeutics (NASDAQ:RPTX), traded on NASDAQ under the symbol RPTX, is a clinical-stage biopharmaceutical company focused on the discovery and development of precision oncology medicines. The company applies synthetic lethality—a concept whereby cancer-specific genetic vulnerabilities are exploited—to design small-molecule therapies that selectively kill tumor cells while sparing healthy tissue. Repare’s proprietary functional genomics and screening platform integrates CRISPR-based assays and computational biology to systematically uncover novel genetic interactions and therapeutic targets.
At the core of Repare’s approach is its ability to identify and validate DNA damage response (DDR)-related targets. The company’s most advanced candidate, RP-3500, is a potent and selective inhibitor of PARP1, currently in Phase 1/2 clinical trials for patients with DDR-deficient solid tumors. Beyond PARP inhibition, Repare is advancing additional programs against polymerase theta (POLθ) and other synthetic lethality partners, with several preclinical assets showing promising activity in tumor models resistant to standard therapies.
Founded in 2016 and headquartered in Montreal, Canada, Repare also maintains operations in Cambridge, Massachusetts, to support its U.S. clinical and research efforts. The company has forged collaborations with leading academic centers and leverages global trial networks to accelerate the clinical development of its pipeline. Repare’s work addresses a broad range of solid tumors, including breast, ovarian, prostate and lung cancers characterized by defects in DNA repair pathways.
Repare Therapeutics is led by President and Chief Executive Officer Derica Shrivastava, a biotechnology executive with over two decades of experience in oncology drug development. Under his leadership, the company has raised multiple financing rounds to fund its research and clinical programs and has built an interdisciplinary team of experts in genomics, medicinal chemistry and translational science. Repare continues to pursue its mission of delivering targeted treatments for patients whose tumors harbor exploitable genetic weaknesses.
